BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23408333)

  • 21. The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels.
    Bajetta E; Ferrari L; Celio L; Mariani L; Miceli R; Di Leo A; Zilembo N; Buzzoni R; Spagnoli I; Martinetti A; Bichisao E; Seregni E
    J Steroid Biochem Mol Biol; 1997; 63(4-6):261-7. PubMed ID: 9459192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy.
    Gallicchio L; MacDonald R; Wood B; Rushovich E; Helzlsouer KJ
    Climacteric; 2012 Aug; 15(4):339-49. PubMed ID: 22191462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
    Li H; Sereika SM; Marsland AL; Conley YP; Bender CM
    J Clin Nurs; 2019 Dec; 28(23-24):4560-4571. PubMed ID: 31469461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
    Ferrari L; Martinetti A; Zilembo N; Pozzi P; Buzzoni R; La Torre I; Gattinoni L; Catena L; Vitali M; Celio L; Seregni E; Bombardieri E; Bajetta E
    J Steroid Biochem Mol Biol; 2002 Apr; 80(4-5):411-8. PubMed ID: 11983488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer.
    Henry NL; Conlon A; Kidwell KM; Griffith K; Smerage JB; Schott AF; Hayes DF; Williams DA; Clauw DJ; Harte SE
    J Pain; 2014 May; 15(5):468-75. PubMed ID: 24462504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
    Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
    Schernhammer ES; Holly JM; Pollak MN; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin may protect nondiabetic breast cancer women from metastasis.
    El-Haggar SM; El-Shitany NA; Mostafa MF; El-Bassiouny NA
    Clin Exp Metastasis; 2016 Apr; 33(4):339-57. PubMed ID: 26902691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IGF status is altered by tamoxifen in patients with breast cancer.
    Campbell MJ; Woodside JV; Secker-Walker J; Titcomb A; Leathem AJ
    Mol Pathol; 2001 Oct; 54(5):307-10. PubMed ID: 11577172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased Igf-I/Igfbp-3 Ratios in Postmenopausal Taiwanese with Breast Cancer, Irrespective of Er and Pr Statuses and Her2 Expression in a Case-Control Study.
    Lee SC; Tsai SM; Hou MF; Tien LY; Wu SH; Hou LA; Tsai JM; Tsai LY
    J Clin Lab Anal; 2016 Jan; 30(1):58-64. PubMed ID: 25385317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
    Martínez N; Herrera M; Frías L; Provencio M; Pérez-Carrión R; Díaz V; Morse M; Crespo MC
    Clin Transl Oncol; 2019 Apr; 21(4):489-498. PubMed ID: 30293230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.
    Papadakis GZ; Mavroudis D; Georgoulias V; Souglakos J; Alegakis AK; Samonis G; Bagci U; Makrigiannakis A; Zoras O
    Growth Horm IGF Res; 2017 Apr; 33():28-34. PubMed ID: 28258988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
    Crew KD; Capodice JL; Greenlee H; Apollo A; Jacobson JS; Raptis G; Blozie K; Sierra A; Hershman DL
    J Cancer Surviv; 2007 Dec; 1(4):283-91. PubMed ID: 18648963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
    Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
    Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
    Torrisi R; Baglietto L; Johansson H; Veronesi G; Bonanni B; Guerrieri-Gonzaga A; Ballardini B; Decensi A
    Br J Cancer; 2001 Dec; 85(12):1838-41. PubMed ID: 11747323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.
    Baglietto L; English DR; Hopper JL; Morris HA; Tilley WD; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):763-8. PubMed ID: 17416768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of treatment with onapristone on the IGF-system in breast cancer patients.
    Helle SI; Jonat W; Giurescu M; Ekse D; Holly JM; Lønning PE
    J Steroid Biochem Mol Biol; 1998 Aug; 66(3):159-63. PubMed ID: 9719450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, Pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients.
    Helle SI; Anker GB; Tally M; Hall K; Lønning PE
    J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):167-71. PubMed ID: 8645625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
    Shanmugam VK; McCloskey J; Elston B; Allison SJ; Eng-Wong J
    Breast Cancer Res Treat; 2012 Jan; 131(2):699-708. PubMed ID: 22076476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.